GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS): This Company’s Debt Might Be a Concern

Page 1 of 2

GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies. If these allegations are substantiated — Glaxo officials at the highest levels have acknowledged that company executives might have broken the law — they could have serious ramifications for the firm’s future. By some accounts, however, these entanglements are simply the price of doing business, something that companies move beyond in the course of things.

But, does GlaxoSmithKline plc (ADR) (NYSE:GSK) enjoy enough financial strength to withstand these pressures? A study of its numbers seemingly does not indicate that is the case; this United Kingdom-based company is carrying too much debt to slide though rough times.

GlaxoSmithKline plc (ADR) (NYSE:GSK)Value investors carefully scrutinize a company’s debt/equity ratio. And GlaxoSmithKline plc (ADR) (NYSE:GSK)’s debt/equity ratio (for the most recent quarter) was 253.66, clearly high enough to set off warning signals, even if it does not mean that this pharmaceutical company stands in eminent danger of becoming “insolvent.” Also troubling, Glaxo’s revenue and earnings have been not been rising, an indication that any funds it is accumulating through borrowing have not been utilized in ways that spurred growth. Its year over year quarterly earnings growth (as of June 30, 2013) was (26.50)% and its year to quarterly revenue growth for the same period was (2.50)%.

And not surprisingly, the credit rating agencies have taken note of GlaxoSmithKline plc (ADR) (NYSE:GSK)’s debt. Earlier this summer, Moody’s cut the outlook on Glaxo’s long-term A1 rating to “negative” from “stable.” In making that move, it cited concerns not only about the company’s debt, but also about massive legal settlements it has been obliged to pay. These payments evolved from marketing strategies designed to pump up sales of its diabetes drug Avandia and its antidepressant Wellbutrin rather than from the Chinese “scandal.”

And GlaxoSmithKline plc (ADR) (NYSE:GSK) recently received other troubling news. India’s Intellectual Property Appellate Board (IPAB) revoked the patent that it held on its breast cancer drug Tykerg, a salt form of lapatinib. The challenge that resulted in this judgment came not from an Indian company, but from the Indian unit of the German drug maker Fresenius Kabi.

Decisions of this type might become more common in the future and greatly impede the potential of Glaxo and other pharmaceutical companies to expand their sales into developing countries.

Some alternatives

If investors prefer a European pharmaceutical company to an American one, but are leery of GlaxoSmithKline plc (ADR) (NYSE:GSK), they do have two alternatives: Novartis AG (ADR) (NYSE:NVS) and AstraZeneca plc (ADR) (NYSE:AZN).

However, while some of the fundamentals these firms have might be more impressive than GlaxoSmithKline plc (ADR) (NYSE:GSK)’s, they are hardly stellar. Novartis AG (ADR) (NYSE:NVS) had a debt/equity ratio (for the most recent quarter) of 27.10, hardly the 1.00 or less that is considered optimum. And its year over year revenue growth for the quarter ending on March 31, 2013, was only 1.10% while quarterly earnings growth for the same period was (5.00)%, hardly a reflection of robust profitability.

But, it is sometimes difficult to predict future results based on the past or even the present performances, and there is reason to believe that Novartis AG (ADR) (NYSE:NVS)’ prospects might be brighter than its current fundamentals would indicate. It continues to lead the industry with 56 new approvals in the U.S., Europe, Japan, and China since 2007. In 2012 alone, the Pharmaceuticals division received nine approvals or positive recommendations to date. One of the most promising new additions to Norvatis’ catalog is Afinitor, an oncology drug. Analysts predict that it has the potential to exceed sales of $2 billion for the treatment of breast cancer alone by 2017.

The United Kingdom-based AstraZeneca plc (ADR) (NYSE:AZN), meanwhile, had an unimpressive debt/equity ratio (for the most recent quarter) of 45.42. And for the quarter ending on March 31, 2013, its year over year quarterly revenue decline was 13.10% and its quarterly earnings fall was an even more troublesome 37.80%.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!